Skip to main content

Biogen (NASDAQ: BIIB) — Company Overview, News & Financial Data

Biogen logo
BIIB Biogen
Biogen primary media
Company profile

Biogen

About

Explore United States companies

Biogen is a global biotechnology company specializing in the discovery, development, and delivery of therapies for neurological, neurodegenerative, rare, and autoimmune diseases. Headquartered in Cambridge, Massachusetts, the company focuses on serious conditions such as multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, Friedreich's ataxia, and postpartum depression. Its portfolio includes prescription biopharmaceuticals, monoclonal antibodies, gene-silencing therapies, and biosimilar products. Biogen maintains international headquarters in Baar, Switzerland, alongside commercial footprint, research facilities, and manufacturing sites across North America, Europe, Asia-Pacific, Latin America, and the Middle East.

Snapshot

Public USOwnership
1978Year founded
5,001–10,000Employees
Cambridge, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Newton, US
Cambridge, US
United States
Switzerland
Japan
Australia

Products and/or services of Biogen

  • Multiple Sclerosis Therapies: Commercialization of oral, injectable, and infusion prescription therapies designed to reduce relapse rates and slow disability progression in adults diagnosed with relapsing forms of multiple sclerosis across major global healthcare markets.
  • Spinal Muscular Atrophy Treatments: Delivery of intrathecally administered antisense oligonucleotide medications that target SMN2 pre-mRNA splicing to treat pediatric and adult patients affected by spinal muscular atrophy in commercial markets worldwide.
  • Alzheimer's Disease Treatments: Development and commercial distribution of humanized monoclonal antibodies targeting amyloid-beta soluble aggregates and protofibrils, engineered to slow cognitive and functional decline in early-stage Alzheimer's disease patients.
  • Rare Disease Therapies: Production and supply of targeted small-molecule and oligonucleotide therapeutics for neurodegenerative rare conditions, including Friedreich ataxia and superoxide dismutase 1 mutation-associated amyotrophic lateral sclerosis.
  • Neuropsychiatry Therapies: Commercialization of oral neuroactive steroid positive allosteric modulators of GABAA receptors prescribed for the treatment of postpartum depression in adult female patients across clinical healthcare settings.
  • Biosimilars & Biologics Manufacturing: Manufacturing and distribution of anti-TNF biosimilar monoclonal antibodies for inflammatory diseases, alongside specialized biopharmaceutical contract manufacturing services for external corporate partners through biologics production facilities.

Biogen executive team

  • Christopher A. ViehbacherPresident, CEO & Director
  • Robin C. KramerExecutive VP & CFO
  • Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology
  • Priya SinghalExecutive VP & Head of Development
  • Sean GodboutVP, Chief Accounting Officer & Global Corporate Controller
  • Guy HadariChief Information Officer
  • Tim PowerHead of Investor Relations
  • Michael John PariniChief Legal Officer
  • Natacha GassenbachChief Communication Officer & Head of Corporate Affairs
  • Adam KeeneyExecutive VP & Head of Corporate Development